Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 4/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.63 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15869885 | 0.90 | ADORA2B (0.62) | ADORA2BADORA2AMAOBTHRBMEN1 | |
| SCHEMBL14907928 | 0.83 | SMN1; SMN2 (0.53) | MEN1KMT2AHTT | |
| SCHEMBL593805 | 0.81 | ADORA2B (0.77) | ADORA2BADORA2AMAOB | |
| SCHEMBL14893396 | 0.80 | ADORA2B (0.59) | ADORA2BADORA2AMAOBTHRBMEN1 | |
| SCHEMBL15869888 | 0.79 | SMN1; SMN2 (0.49) | MEN1KMT2AHTT | |
| SCHEMBL14893220 | 0.78 | ADORA2A (0.60) | ADORA2BADORA2AMAOBTHRBMEN1 | |
| SCHEMBL1347557 | 0.78 | ADORA2A (0.73) | ADORA2BADORA2AMAOBMAOA | |
| SCHEMBL4146728 | 0.78 | ADORA2B (1.00) | ADORA2BADORA2AMAOBMAOAHTT | |
| SCHEMBL593636 | 0.78 | ADORA2B (0.68) | ADORA2BADORA2AMAOBTHRBKMT2A | |
| SCHEMBL25090598 | 0.77 | ADORA2B (0.59) | ADORA2BADORA2AMAOBTHRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753333-B1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED INC (US) | 2017-06-21 | — | — | EP | disclosed |
| CN-104010641-B | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | 普罗塔医药公司 | 2017-04-12 | — | — | CN | disclosed |
| US-9169255-B2 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | PROTEO TECH INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169255-B2 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | PROTEO TECH INC. (US) | 2015-10-27 | — | — | US | disclosed |
| CN-104010641-A | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | PROTEOTECH INC | 2014-08-27 | — | — | CN | disclosed |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED, INC. | 2014-07-10 | — | — | US | disclosed |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED, INC. | 2014-07-10 | — | — | US | disclosed |
| WO-2013062762-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | SNCA, PARK7, APP | ADORA2B 3019/4885ADORA2A 2640/4885MAOB 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.